BioNexus Gene Lab files initial beneficial ownership statement for Fidelion Diagnostics Pte. Ltd

Reuters2026/08/07 20:28

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

BioNexus Gene Lab filed a Form 3 showing Fidelion Diagnostics beneficially owns 392,329 common shares as of Nov. 28, 2025.
The filing classifies Fidelion Diagnostics as a greater-than-5% holder.
No derivative securities were reported.
The Form 3 was signed by Ling Xiao on Aug. 4, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioNexus Gene Lab Corp. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001520138-26-000322), on August 07, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

BioNexus Gene Lab files initial beneficial ownership statement for Fidelion Diagnostics Pte. Ltd

You may also like

Crypto prices